Purchase this article with an account.
LUDWIG VON SALLMANN, PATRICIA GRIMES; The Cataractogenic Effect of Dibromomannitol in Rats. Invest. Ophthalmol. Vis. Sci. 1970;9(4):291-299.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Dibromomannitol (DBM) is one of the new chemotherapeutic compounds beneficial in the treatmentof chronic myelogenous leukemia. Investigation of the effects of the drug on the rat lens has demonstrated that it exerts a complex cytotoxic action on the epithelial population and, with prolonged administration, is cataractogenic in normal animals. The response to DBM only partially resembles that evoked by Myleran, a related drug known to induce cataracts in rats.
This PDF is available to Subscribers Only